G42 Healthcare strengthens clinical genomics offering

G42 Healthcare strengthens clinical genomics offering

- New solution to empower accurate interpretation of Next-Generation Sequencing data

- Expanded offerings to make personalized treatment options a reality in UAE and region

Abu Dhabi: In a step aimed at boosting its clinical genomics capabilities in the region and beyond, G42 Healthcare, Abu Dhabi-based leading AI health-tech company, has announced a partnership with Saphetor SA, a Swiss precision medicine company and creator of the VarSome suite of bioinformatics solutions.

The collaboration is a pivotal step in G42 Healthcare’s strategy to support the health of future generations, in addition to reinforcing the UAE’s reputation as the hub for global innovation and research in the field of clinical genomics.

Saphetor’s VarSome Clinical – a clinically-certified cloud-based platform empowering fast and accurate variant discovery, annotation, and interpretation of Next Generation Sequencing data – complements G42 Healthcare’s robust capabilities of sequencing data more rapidly and precisely, helping biologists, geneticists, and doctors to push the boundaries of healthcare innovation and discovery.

Enhancing these new capabilities is part of G42 Healthcare’s mission to provide insights and facilitate early diagnosis and treatment of cancer, rare and metabolic diseases, and other genetic conditions in the region. The company recently launched over 250 comprehensive clinical genetic testing panels that use state-of-the-art sequencing